Skip NavigationMarketsBusinessInvestingTechPoliticsVideoWatchlistInvesting Club
PRO
LivestreamMenuHere are the biggest calls on Wall Street on Thursday: Bank of America reiterates Apple as buy The firm says it thinks price increases are already built into the stock. “In an exclusive interview with the Wall Street Journal, outgoing CEO Tim Cook noted that Apple i s forced to raise pricing to offset the impact of escalating memory costs. We had already expected Apple to raise pricing and had reflected about $100 price increase in our prior estimates.” DA Davidson upgrades Nice to buy from neutral DA Davidson says concerns about AI disruption are overblown. “We are upgrading shares of NICE from neutral to BUY (maintaining $110 PT, 9x ’27 EPS) after conversations with customers at the company’s annual user event last week suggested investors’ perception of AI disruption is much more cynical than the reality occurring within contact centers.” Bank of America initiates Immix Biopharma as buy Bank of America says the biopharma company has a differentiated offering. “We initiate coverage of IMMX with a Buy rating and $27 PO.” Jefferies initiates Iren as buy Jefferies says the bitcoin miner is firing on all cylinders. “IREN has positioned itself in a unique place among AI infrastructure providers with an extraordinarily large long-term powered land bank (~6 GW) and a vertically integrated GPU cloud approach.” Jefferies initiates Targa Resources as buy The firm says the midstream company has plenty of upside. “We differentiate in our conviction that TRGP will sustain its premium growth through FY30 as outlined by its 3-plant pa. model, but cons. is yet to underwrite the full potential, particularly in FY29/30.” Barclays initiates Indivior Pharmaceuticals as overweight Barclays says it’s bullish on the biopharma company. “We see additional upside over the balance of FY26 driven by INDV’s strong commercial execution amid a turnaround plan…” Citi upgrades Albemarle to buy from neutral Citi says the stock is undervalued. “We believe current valuation levels underappreciate ALB’s next leg of growth and upgrade to Buy with no change to our $225 TP.” Jefferies reiterates Amazon as buy Jefferies says it’s bullish on the company’s partnership between AWS and OpenAI. “We expect AWS growth to accel to 31% y/y in ’26 vs. 20% in ’25. AMZN remains one of our top 2H26 picks.” KeyBanc reiterates Marvell as overweight The firm raised its price target on Marvell from $385 per share from $260. “We introduce FY29E and, given our more constructive view, raise our ests and increase PT to $385.” Read more. Rosenblatt reiterates Micron as buy Rosenblatt raised its price target on Micron to $1,200 from $600 ahead of earnings next week. “We expect Micron to report a beat-and-raise as continued pricing increases, broadening AI demand, and constrained supply extend the memory upcycle.” Jefferies initiates Copa Holdings and LatAm Airlines as buy The firm initiated coverage of LatAm and Copa and says both airlines are well positioned. “Mid-term, we see the sector supported by increasing air travel penetration and more rational competition.” Loop reiterates Palantir as buy Loop says it’s sticking with the stock after a meeting with the company. “Through that lens, we think Palantir’s premium valuation may be better understood not as a reflection of its current revenue and earnings profile, but as the market assigning value to the possibility that the company is building the next foundational software layer for industrial enterprises.” Goldman Sachs initiates Talen Energy as buy Goldman says the energy and power company has a slew of positive catalysts ahead. “We initiate on TLN with a Buy rating, as we believe its 17-year AWS power purchase agreement (PPA) has structurally de-risked cash flows…” Barclays reiterates Nike as overweight Barclays says it’s sticking with the stock for the “long-term opportunity.” “At current valuation levels, NKE refllects a turnaround/restructuring story, replacing its historic positioning as a premium global growth story. ” Stifel downgrades Intuit to hold from buy Stifel says it sees “share erosion.” “Downgrading INTU to Hold as we expect management to lower its near/medium growth targets for both TurboTax and GBS with 4Q results/Sept analyst day as the company, after years of relentlessly taking price, moves to a more value-based pricing strategy, especially at the lower end of each business segment, to arrest recent share erosion.” Arete initiates SpaceX as buy The firm says the space company has plenty of upside. “We initiate on SpaceX with a Buy rating and DCF-based $401 ’27E price target, reflecting the scale of opportunities we see in Space, Connectivity and AI, without considering additional markets.” KBW upgrades CME to outperform from market perform KBW says the stock is too attractive to ignore at current levels. “We are upgrading CME to Outperform from Market-Perform. While we had expected the stock to be under pressure post 1Q, we have seen a downward acceleration in recent weeks, which is creating an attractive risk/reward.” RBC initiates Praxis Precision Medicines as outperform RBC said in its initiation of Praxis that the biopharma company is undervalued. “As future revenues trade at a discount to other CNS [central nervous system] peers, we think regulatory de-risking can help bridge the gap, and we see potential for shares to double on success.” Barclays upgades UniQure to overweight from equal weight Barclay says it’s bullish on the company’s treatment for neurodegenerative disorder Huntington’s. We upgrade QURE to OW and raise our our PT to $65/sh after FDA regulatory update which per QURE enables filing for accelerated approval in Huntington’s. Oppenheimer reiterates SpaceX as outperform The firm raised its price target on shares of SpaceX. “We have extended our model out five years and raised near-term estimates; our new PT is $250 (was $190).” Monness Crespi Hardt upgrades Salesforce to buy from neutral Monness upgraded Salesforce and says the stock is compelling. “Given Salesforce’s depressed valuation, attractive margin profile, strong cash flow generation, generous stock repurchase program, and progress in supporting customers transforming into agentic enterprises, we are upgrading our rating on Salesforce to Buy from Neutral and assigning a 12-month price target of $200.”Read More
About The Author
